Contracts › 75N95024F00001
75N95024F00001: Investigational Agent Single Ascending Dose Safety, Tolerability, and Pk Study. September 3, 2024 to March 2, 2026. N01DA-23-8935
Awarded to Altasciences Clinical Kansas Inc by National Institutes of Health (NIH).
$1.7Mobligated
$1.7Mpotential value
10 March 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N95024F00001 |
|---|---|
| Vehicle | 75N95023D00019 |
| Awardee | Altasciences Clinical Kansas Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | KS |
| Period of performance | 12 September 2024 to 10 March 2027 |
| Potential end | 10 March 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record